Gastroparesis in Diabetes Clinical Insights and Management Strategies

Gibbons Nakane^*
*Correspondence: Gibbons Nakane, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA, Email:

Introduction

Gastroparesis, a condition characterized by delayed gastric emptying, is frequently observed in patients with diabetes, particularly those with type 1 and type 2 diabetes mellitus. This review provides a comprehensive overview of the pathophysiology, clinical presentation, diagnostic approaches, and management strategies for diabetic gastroparesis. By synthesizing current literature and clinical insights, we aim to enhance the understanding of this complex disorder and its impact on diabetes management. Gastroparesis is a gastrointestinal disorder that impairs the normal motility of the stomach, leading to delayed gastric emptying. In diabetic patients, the condition is often attributed to autonomic neuropathy resulting from chronic hyperglycemia. The prevalence of gastroparesis in diabetes varies, with estimates ranging from 20% to 50% in patients with type 1 diabetes and around 30% in those with type 2 diabetes. This condition significantly affects glycemic control, nutritional status, and overall quality of life.

The underlying pathophysiology of diabetic gastroparesis primarily involves damage to the enteric nervous system and autonomic neuropathy. Chronic hyperglycemia leads to neuronal degeneration and impaired gastric motility. Key factors contributing to the development of gastroparesis in diabetic patients include Autonomic Neuropathy Damage to the vagus nerve impairs the regulation of gastric motility. Altered Gastric Secretions Changes in gastric acid and hormone secretion can affect digestion and motility. Gastric Emptying Mechanisms Disruption in the coordinated contractions of gastric muscles results in delayed emptying [1].

Description

<p>The symptoms of gastroparesis can be diverse and often overlap with other gastrointestinal disorders. Common symptoms include:</p>
<p>&bull; Nausea and vomiting</p>
<p>&bull; Early satiety</p>
<p>&bull; Bloating</p>
<p>&bull; Abdominal pain or discomfort</p>
<p>&bull; Weight loss</p>
<p>&bull; Fluctuations in blood glucose levels</p>
<p>Due to these nonspecific symptoms, diagnosis can be challenging. It is essential for clinicians to consider gastroparesis in patients with diabetes presenting with gastrointestinal complaints, particularly if they have significant glycemic variability. Diagnosing gastroparesis typically involves a combination of clinical assessment and diagnostic testing. The following steps are crucial in the diagnostic process:</p>
<p><strong>Clinical history:</strong> A thorough history focusing on symptoms, duration, and any prior gastrointestinal issues.</p>
<p><strong>Physical examination:</strong> Assessing for signs of dehydration, malnutrition, and abdominal tenderness.</p>
<p><strong>Gastric emptying studies:</strong> The gold standard for diagnosis, usually performed using a scintigraphy test where a radiolabeled meal is ingested, and images are taken over several hours.</p>
<p><strong>Other tests:</strong> In some cases, additional tests such as breath tests, endoscopy, or MRI may be indicated to rule out other conditions [<a href="#2" title="2">2</a>].</p>
<p>Management of gastroparesis in diabetes involves a multifaceted approach, including lifestyle modifications, dietary adjustments, pharmacotherapy, and in some cases, surgical interventions. Dietary changes , more frequent meals that are low in fat and fiber can help reduce symptoms. Soft, easily digestible foods are often recommended. Hydration, maintaining adequate hydration is crucial, especially in patients experiencing nausea and vomiting. Prokinetic agents, medications like metoclopramide and domperidone can enhance gastric motility and alleviate symptoms. However, metoclopramide has potential side effects, including tardive dyskinesia, and should be used cautiously. Drugs such as ondansetron can help control nausea and vomiting. Tight glycemic control may improve gastroparesis symptoms. Adjusting insulin regimens and monitoring blood glucose levels closely are vital. For patients who cannot maintain adequate nutrition, enteral feeding may be necessary. Using commercial enteral nutrition formulas that are easier to digest. Total Parenteral Nutrition (TPN): In severe cases, TPN may be required, though this is generally a last resort due to potential complications. Gastric electrical stimulation involves implanting a device that sends electrical impulses to the stomach muscles, improving motility [<a href="#3" title="3">3</a>].</p>
<p>Managing diabetic gastroparesis often requires a team approach involving endocrinologists, gastroenterologists, dietitians, and diabetes educators. Regular follow-ups are essential to adjust management strategies based on the patient&rsquo;s response. Patients with gastroparesis may experience erratic blood glucose levels due to delayed gastric emptying. Therefore, continuous glucose monitoring and adjustments in insulin therapy are vital for maintaining glycemic control. Educating patients about their condition, dietary choices, and self-management techniques is crucial. Providing resources and support can empower patients to take an active role in managing their symptoms. Future research should aim to elucidate the complex pathophysiological mechanisms underlying diabetic gastroparesis. Investigating the role of inflammation, gut microbiota, and genetic predisposition in the development of this condition may lead to novel therapeutic targets. Additionally, studying the effects of long-term glycemic control on gastric motility could provide insights into preventative strategies for at-risk patients.</p>
<p>Current pharmacological options for managing gastroparesis are limited, and there is a significant need for new medications. Research into novel prokinetic agents, as well as alternatives such as cannabinoid-based therapies, could offer new avenues for treatment. Furthermore, exploring the use of glucagon-like peptide-1 (GLP-1) agonists, which have been shown to affect gastric emptying, may provide additional therapeutic strategies [<a href="#4" title="4">4</a>].</p>
<p>Advancements in technology, such as the development of wearable devices for real-time monitoring of gastric motility, could enhance diagnosis and management. Integrating continuous glucose monitoring with gastric emptying assessments could provide valuable data for personalizing diabetes treatment in patients with gastroparesis. Research should focus on the psychological and emotional impact of gastroparesis on patients with diabetes. Understanding how symptoms affect mental health and quality of life can lead to more holistic management strategies that address both physical and psychological needs. Moreover, studies exploring the effectiveness of patient education programs in improving self-management and adherence to treatment plans could prove beneficial. The development of comprehensive clinical guidelines specifically addressing the management of gastroparesis in diabetic patients is needed. These guidelines should incorporate evidence-based recommendations for diagnosis, treatment, and follow-up care, helping to standardize practices across healthcare settings [<a href="#5" title="5">5</a>].</p>
    

Conclusion

Gastroparesis remains a significant yet often overlooked complication of diabetes that poses unique challenges in clinical management. As our understanding of this disorder evolves, so too must our approaches to diagnosis and treatment. By prioritizing research, fostering multidisciplinary collaboration, and emphasizing patient education, healthcare providers can improve outcomes for individuals living with diabetic gastroparesis. Addressing this condition with the attention it deserves will ultimately enhance the overall management of diabetes and improve the quality of life for countless patients.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Marini, Alessandro, Andrea Bernardini, Gian Luigi Gigli and Mariarosaria Valente, et al. "Neurologic adverse events of immune checkpoint inhibitors: A systematic review." Neurology 96 (2021): 754-766.

Google Scholar, Cross Ref, Indexed at

2. Pizuorno Machado, Antonio, Malek Shatila, Cynthia Liu and Jianbo Wang, et al. "Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases." J Cancer Res Clin Oncol 149 (2023): 6341-6350.

Google Scholar, Cross Ref, Indexed at

3. Abu-Sbeih, Hamzah, David M. Faleck, Biagio Ricciuti and Robin B. Mendelsohn, et al. "Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease." J Clin Oncol 38 (2020): 576-583.

Google Scholar, Cross Ref, Indexed at

4. Chikkamenahalli, Lakshmikanth L., Erik Jessen, Cheryl E. Bernard and WK Eddie Ip, et al. "Single cell atlas of human gastric muscle immune cells and macrophage-driven changes in idiopathic gastroparesis." Iscience 27 (2024).

Google Scholar, Cross Ref, Indexed at

5. Revicki, Dennis A., Anne M. Rentz, Dominique Dubois and Peter Kahrilas, et al. "Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms." Qual Life Res 13 (2004): 833-844.

Google Scholar, Cross Ref, Indexed at